scholarly journals Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes

2007 ◽  
Vol 88 (2) ◽  
pp. 428-431 ◽  
Author(s):  
Armen Parsyan ◽  
Camille Szmaragd ◽  
Jean-Pierre Allain ◽  
Daniel Candotti
Keyword(s):  
Genetic Diversity ◽  
Parvovirus B19 ◽  
Divergence Time ◽  
Mutation Rates ◽  
Human Parvovirus B19 ◽  
Genotype 1 ◽  
Genotype 3 ◽  
Nucleotide Substitutions ◽  
The Family

Three genotypes (1–3) of human parvovirus B19 have been identified. Analysis of 13 nearly full-length genotype 3 sequences from Ghana, Europe and Brazil identified two genetically distinct clusters. The classification of genotype 3 strains into two subtypes (B19/3a and B19/3b) is proposed. The rate of evolutionary change of B19 genotype 3 strains (2×10−4 nucleotide substitutions per site per year) was similar to those of B19 genotype 1 and carnivore parvoviruses, supporting the hypothesis that high mutation rates are characteristic of members of the family Parvoviridae. The estimated divergence time between B19/3a and B19/3b is 525 years. In Ghana, subtype B19/3a is predominant.

scholarly journals Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients

2006 ◽  
Vol 87 (10) ◽  
pp. 2941-2949 ◽  
Author(s):  
Nguyen L. Toan ◽  
Anja Duechting ◽  
Peter G. Kremsner ◽  
Le H. Song ◽  
Martin Ebinger ◽  
...  
Keyword(s):  
Phylogenetic Analysis ◽  
Hepatitis B Virus ◽  
Parvovirus B19 ◽  
Human Parvovirus B19 ◽  
Genotype 1 ◽  
Genotype 3 ◽  
Nucleotide Difference ◽  
Genotype 2 ◽  
B Virus ◽  
The Mean

Recently, three distinct genotypes (1, 2 and 3) of human parvovirus B19 (B19) have been identified. However, the characteristics and distribution of B19 genotypes in Vietnam have not been investigated. Phylogenetic analysis using 49 subgenomic NS1/VP1u regions and two coding NS1–VP1/VP2 regions has been applied to investigate the prevalence of B19 genotypes in Vietnamese patients co-infected with Hepatitis B virus. Genetic analysis of the subgenomic NS1/VP1u region of B19 revealed that two genotypes of B19 were identified in these populations, with predominance of genotype 1 (47/49, 96 %) followed by genotype 2 (2/49, 4 %), but not genotype 3. Further, phylogenetic analysis of subgenomic B19 genomes revealed two major subgroups within genotype 1 (B19-1A and B19-1B) with an estimated nucleotide difference of >5 % between each subgroup, forming different branches. The mean percentage of amino acid variation between subgroup B19-1A and B19-1B was >2 % of the NS1, VP1 and VP2 proteins. Our results indicated that two of the three known genotypes of B19 were present in Vietnamese patients, with genotype 1 predominating, and that this genotype can be classified into at least two subgroups, B19-1A and B19-1B.

scholarly journals Simultaneous persistence of multiple genome variants of human parvovirus B19

2008 ◽  
Vol 89 (1) ◽  
pp. 164-176 ◽  
Author(s):  
Beate Schneider ◽  
Andrea Höne ◽  
René H. Tolba ◽  
Hans-Peter Fischer ◽  
Johannes Blümel ◽  
...  
Keyword(s):  
Parvovirus B19 ◽  
Acute Infection ◽  
Human Parvovirus B19 ◽  
Genotype 1 ◽  
Genotype 3 ◽  
Viral Dna ◽  
Antiviral Immune Response ◽  
Sequence Heterogeneity ◽  
Genotype 2 ◽  
Genome Variants

The species human parvovirus B19 (B19V) can be divided into three genotypes. In this study, we addressed the question as to whether infection of an individual is restricted to one genotype. As viral DNA is detectable in tissue for long times after acute infection, we examined 87 liver specimens from adults for the presence of B19V DNA. Fifty-nine samples were found to be positive, 32 of them for genotype 1, 27 for genotype 2 and four for genotype 3. In four samples, DNA of two genotypes was detected; samples from three individuals were positive for genotypes 1 and 2 and a sample from one individual was positive for genotypes 1 and 3. Surprisingly, significant sequence heterogeneity was observed at approximately 1 % of the nucleotides of the genotype 1 genomes from individuals with double genotype 1 and 2 infection. Controls using different enzymes for genome amplification and dilutions of the template verified that nucleotide heterogeneity was due to the presence of three or more genome variants of genotype 1. In summary, the evidence shows that individuals can be infected with two different genotypes, and B19V DNA can persist as a population of different genomes. The results may have implications for the understanding of the antiviral immune response and the development of vaccines against B19V.

scholarly journals Identification and Characterization of Persistent Human Erythrovirus Infection in Blood Donor Samples

2004 ◽  
Vol 78 (22) ◽  
pp. 12169-12178 ◽  
Author(s):  
Daniel Candotti ◽  
Nermin Etiz ◽  
Armen Parsyan ◽  
Jean-Pierre Allain
Keyword(s):  
South Africa ◽  
United Kingdom ◽  
Persistent Infection ◽  
Parvovirus B19 ◽  
Sub Saharan Africa ◽  
Genotype 1 ◽  
Genotype 3 ◽  
Real Time Quantitative Pcr ◽  
The United Kingdom ◽  
Sub Saharan

ABSTRACT The presence of human erythrovirus DNA in 2,440 blood donations from the United Kingdom and sub-Saharan Africa (Ghana, Malawi, and South Africa) was screened. Sensitive qualitative and real-time quantitative PCR assays revealed a higher prevalence of persistent infection with the simultaneous presence of immunoglobulin G (IgG) and viral DNA (0.55 to 1.3%) than previously reported. This condition was characterized by a low viral load (median, 558 IU/ml; range, 42 to 135,000 IU/ml), antibody-complexed virus, free specific IgG, and potentially infectious free virus. Human erythrovirus genotype 1 (formerly parvovirus B19) was prevalent in the United Kingdom, Malawi, and South Africa. In contrast, only human erythrovirus genotype 3 (erythrovirus variant V9) was prevalent in Ghana. Genotype 3 had considerable genetic diversity, clustering in two probable subtypes. Genotype 1-based antibody assays failed to detect 38.5% of Ghanaian samples containing antibodies to genotype 3 virus but did not fail to detect cases of persistent infection. This study indicates a potential African origin of genotype 3 human erythrovirus and considerable shortcomings in the tools currently used to diagnose erythrovirus infection.

scholarly journals Human parvovirus B19 genotype 1 in suspected dengue patients of Tefé, Amazonas State, Brazil

2019 ◽  
Vol 52 ◽  
Author(s):  
Regina Maria Pinto de Figueiredo ◽  
Victor Costa de Souza ◽  
Valdinete Alves do Nascimento ◽  
Felipe Gomes Naveca
Keyword(s):  
Parvovirus B19 ◽  
Human Parvovirus B19 ◽  
Genotype 1 ◽  
Amazonas State

scholarly journals Genotype 1 of human parvovirus B19 in clinical cases

2017 ◽  
Vol 63 (3) ◽  
pp. 224-228 ◽  
Author(s):  
Maria Isabel de Oliveira ◽  
Ana Maria Sardinha Afonso ◽  
Suely Pires Curti ◽  
Patrícia Evelin Silva ◽  
Tamyris Fernanda Barbosa ◽  
...  
Keyword(s):  
Parvovirus B19 ◽  
Infectious Agent ◽  
Immunoglobulin M ◽  
Human Parvovirus B19 ◽  
Genotype 1 ◽  
Serum Samples ◽  
Chronic Anemia ◽  
Virus Surveillance ◽  
Polymerase Chain

Summary Introduction: Virus surveillance strategies and genetic characterization of human parvovirus B19 (B19V) are important tools for regional and global control of viral outbreak. In São Paulo, Brazil, we performed a study of B19V by monitoring the spread of this virus, which is an infectious agent and could be mistakenly reported as a rash and other types of infection. Method: Serum samples were subjected to enzyme immunoassay, real time polymerase chain reaction, and sequencing. Results: From the 462 patients with suspected cases of exanthematic infections, the results of the 164 serum samples were positive for B19V immunoglobulin M. Among these cases, there were 38 patients with erythema infections and B19-associated with other infections such as encephalitis, hydrops fetalis, chronic anemia, hematological malignancies. These samples were sequenced and identified as genotype 1. Conclusion: This study showed patients with infections caused by B19V and sequencing genotype 1. Continuous monitoring is necessary to detect all known genotypes, and the emergence of new genotypes of these viruses for case management in public health control activities.

Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2

2004 ◽  
Vol 92 (10) ◽  
pp. 838-845 ◽  
Author(s):  
Beate Schneider ◽  
Maria Becker ◽  
Hans-Hermann Brackmann ◽  
Anna Eis-Hübinger
Keyword(s):  
Parvovirus B19 ◽  
Simultaneous Detection ◽  
Coagulation Factor ◽  
Nucleic Acid Amplification ◽  
Clotting Factor ◽  
Human Parvovirus B19 ◽  
Genotype 1 ◽  
Viral Inactivation ◽  
Genotype 2 ◽  
Coagulation Factor Concentrates

SummaryHuman parvovirus B19 (B19) DNA has frequently been detected in plasma-derived coagulation factor concentrates. Furthermore, transmission of B19 infection was observed, indicating presence of the infectious virus despite routine viral inactivation/removal procedures during the manufacturing process. Recently, human parvovirus DNA isolates, variant from B19, have been identified resulting in classification of B19 virus into three distinct genotypes, with all viruses previously classified as B19 belonging to genotype 1. So far, there is no information available on contamination of clotting factor concentrates with genotype 2. Therefore, we analysed 202 different factor concentrate lots for genotype 1 and 2 DNA by PCR. Analysis of one hundred eighty-one lots representing 13 different products, administered over the last three years, was compared to 21 lots (8 products) used until the early 1980s which had not been treated by viral inactivation procedures. Genotype 1 DNA was detected in 77/181 (42.5%) currently administered lots, and 17/21 (81%) previously used lots. The level of genotype 1 DNA contamination was similar in currently and previously administered concentrates. Genotype 2 DNA was found in 5/202 (2.5%) lots, all of which were co-contaminated with genotype 1 DNA. DNA sequence analysis showed that the PCR-double positive concentrates contained typical genotype 1 and genotype 2 DNA. Because genotype 2 appears to cause a similar spectrum of diseases as genotype 1, simultaneous detection of genotype 2 by nucleic acid amplification testing (NAT), now widely applied to plasma pools for genotype 1, would give an added level of safety to blood products.

Sign in / Sign up

Export Citation Format

Share Document